Mark W. Kieran researcher
Kieran, Marc
VIAF ID: 540144782716878103945 (Personal)
Permalink: http://viaf.org/viaf/540144782716878103945
Preferred Forms
- 100 1 _ ‡a Kieran, Marc
- 100 0 _ ‡a Mark W. Kieran ‡c researcher
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Genomic Profiling of Pediatric Low-Grade Gliomas | |
MB-66PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHLDREN WITH Wnt POSITIVE STANDARD RISK MEDULLOBLASTOMA. | |
MBCL-02. CURRENT ISSUES IN THE MANAGEMENT OF DESMOPLASTIC NODULAR MEDULLOBLASTOMA IN YOUNG CHILDREN | |
Mechanism of pulmonary vein stenosis in infants with normally connected veins | |
Medical, psychological, cognitive and educational late-effects in pediatric low-grade glioma survivors treated with surgery only. | |
Metachronous mediastinal seminoma occurring after intracranial germinoma in an adolescent | |
Metronomic antiangiogenic therapy in children with recurrent brain tumours of different histologies | |
Microbiome at sites of gingival recession in children with Hutchinson-Gilford progeria syndrome | |
Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells | |
Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: Proceedings from the 1st International Costello Syndrome Research Symposium 2007 | |
A monoclonal antibody against chicken MHC class I (B-F) antigens | |
Moyamoya following cranial irradiation for primary brain tumors in children. | |
MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma | |
A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method | |
Multiparametric Analysis of Permeability and ADC Histogram Metrics for Classification of Pediatric Brain Tumors by Tumor Grade. | |
Multiplexed Immunofluorescence Reveals Potential PD-1/PD-L1 Pathway Vulnerabilities in Craniopharyngioma. | |
MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism | |
Myelopoiesis in the zebrafish, Danio rerio. | |
Myxopapillary ependymomas in children: imaging, treatment and outcomes | |
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma | |
Neuropsychological functioning after surgery in children treated for brain tumor | |
Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria | |
New approaches to progeria | |
New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy | |
Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. | |
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. | |
A novel GIT2-BRAF fusion in pilocytic astrocytoma. | |
A novel method for rapid molecular subgrouping of medulloblastoma. | |
NS-26THE ROLE OF SURGERY IN NON-NF-ASSOCIATED PEDIATRIC OPTIC PATHWAY GLIOMAS (OPG) - IS THERE A NEW PARADIGM? | |
Ophthalmologic Features of Progeria | |
Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. | |
Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration | |
Parent-perceived child cognitive function: results from a sample drawn from the US general population | |
PATH-17. INCREASING VALUE OF AUTOPSIES IN PATIENTS WITH BRAIN TUMORS IN THE MOLECULAR ERA | |
Paucicellular Fibrointimal Proliferation Characterizes Pediatric Pulmonary Vein Stenosis: Clinicopathologic Analysis of 213 Samples From 97 Patients | |
PDCT-03. PHASE 1 STUDY OF Ad-RTS-hIL-12 + VELEDIMEX IN PEDIATRIC BRAIN TUMORS | |
PDTM-04. REDEFINING THE CELLULAR ARCHITECTURE OF DIFFUSE MIDLINE GLIOMAS WITH H3 K27M MUTATIONS THROUGH LARGE-SCALE SINGLE-CELL ANALYSES | |
PDTM-06. ALK AMPLIFICATION AND REARRANGEMENTS ARE RECURRENT TARGETABLE EVENTS IN GLIOBLASTOMA | |
Pediatric brainstem gliomas: new understanding leads to potential new treatments for two very different tumors. | |
Pediatric cancer research: Surviving COVID-19 | |
Pediatric high-grade glioma: biologically and clinically in need of new thinking | |
Pediatric neuro-oncology: current status and future directions. | |
A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. | |
Perfusion MRI of U87 brain tumors in a mouse model | |
A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study | |
Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. | |
A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas | |
Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumo | |
Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). | |
A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors | |
A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma | |
A phase II trial of a multi-agent oral antiangiogenic | |
A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyltransferase | |
A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors | |
A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome | |
The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study | |
A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. | |
A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo | |
TBIO-18. LIQUID BIOPSY DETECTION OF GENOMIC ALTERATIONS IN PEDIATRIC BRAIN TUMORS FROM CELL FREE DNA IN PERIPHERAL BLOOD, CSF, AND URINE | |
Therapeutic potential of thiazolidinediones as anticancer agents | |
Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression | |
Time to rethink the unthinkable: upfront biopsy of children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). | |
TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS | |
TR-14A FEASIBILITY AND RANDOMIZED PHASE II STUDY OF VORINOSTAT, BEVACIZUMAB, OR TEMOZOLOMIDE DURING RADIATION FOLLOWED BY MAINTENANCE CHEMOTHERAPY IN NEWLY-DIAGNOSED PEDIATRIC HIGH-GRADE GLIOMA: CHILDREN'S ONCOLOGY GROUP STUDY ACNS0822. | |
Transverse myelitis after therapy for primitive neuroectodermal tumors | |
Treatment of low-grade gliomas in children: an update. | |
TRTH-23. FEASIBILITY AND SAFETY OF SURGICAL BIOPSY FOR PATIENTS WITH DIPG: PRELIMINARY RESULTS FROM DIPG-BATS. | |
Tumor dissemination through surgical tracts in diffuse intrinsic pontine glioma | |
TUMOUR BIOLOGY | |
Type IV collagen α6 chain-derived noncollagenous domain 1 (α6(IV)NC1) inhibits angiogenesis and tumor growth | |
The VEGF pathway in cancer and disease: responses, resistance, and the path forward. | |
Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children | |
Wilms tumor screening is unnecessary in Klippel-Trenaunay syndrome | |
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors |